Gemini: Snapping up SNPs

Gemini Genomics plc is looking to link up with SNP providers to demonstrate medically significant associations between human SNPs and risk factors for a range of common diseases. The clinical genomics company today was to announce its first foray into the SNPs arena, with a large-scale target discovery deal with CuraGen Corp. (CRGN).

The renewable two-year collaboration will seek to associate thousands of CRGN's human genetic variations with disease traits derived from Gemini's database of clinical populations, in order to validate genes and genetic variations that contribute to the onset of complex diseases.